11C Acetate Articles

Articles

11C-acetate PET/MRI in bladder cancer staging and treatment response evaluation to neoadjuvant chemotherapy: a prospective multicenter study (ACEBIB trial).

To evaluate the accuracy of 11C-acetate Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) in bladder cancer (BC) staging and monitoring response to neoadjuvant chemotherapy (NAC).
Eighteen patients were prospectively enrolled.
Published August 7, 2018
Prostate Cancer Imaging with Novel PET Tracers.

Molecular imaging of prostate cancer is in a dynamic phase of development. Currently approved techniques are limited and researchers have been working on novel agents to improve accuracy in targeting and detecting prostate tumors.

Published February 19, 2016
SNMMI 2016: 11C-acetate PET/CT accurately predicts prostate-cancer specific survival in patients with biochemical relapse after prostatectomy
San Diego, CA. USA (UroToday.com) – 11Choline-acetate (11C-acetate) has been used as an investigational PET radiopharmaceutical to image patients with prostate cancer based on elevated transports in prostate cancers after prostatectomy to detect recurrence and metastasis upon biochemical relapse. Its utility for predicting outcomes in this group of patients has not been reported. Naresh Kumar Regula, from the Uppsala University, Sweden presented new data at the 2016 Society of Nuclear Medicine and Molecular Imaging annual meeting. The question of whether parameters measured by 11C-acetate PET correlate with clinical outcomes including survival.

Published July 11, 2016

11C Acetate Articles

Articles

11C-acetate PET/MRI in bladder cancer staging and treatment response evaluation to neoadjuvant chemotherapy: a prospective multicenter study (ACEBIB trial).

Prostate Cancer Imaging with Novel PET Tracers.

SNMMI 2016: 11C-acetate PET/CT accurately predicts prostate-cancer specific survival in patients with biochemical relapse after prostatectomy

Login